ONCY — Oncolytics Biotech Share News
0.000.00%
Brief: Oncolytics Says Pelareorep Shows Durable Survival Benefit in Anal Cancer
Brief: Oncolytics Biotech Expects Final Cohort 4 Results Of Goblet Study In Q4 2026
Brief: Oncolytics Biotech® Secures Patent Protection To Late 2040S And Provides Intellectual Property Portfolio Update
Brief: Oncolytics Biotech® Aligns With FDA On Registrational Path For Second-Line Ras-Mutant Mss Colorectal Cancer
Brief: Oncolytics Biotech Announces New US Patent For Pelareorep Manufacturing Process
Brief: Oncolytics Biotech® Reports Durable Responses In Second-Line Ras-Mutant Mss Colorectal Cancer
Brief: Oncolytics Biotech Inc Announces Alignment With FDA On Pivotal Anal Cancer Study
U.S. STOCKS ON THE MOVE-Tesla, Norfolk Southern, Denali
U.S. STOCKS ON THE MOVE-Tyson Foods, Atmus Filtration, Avis Budget
Oncolytics rises as it schedules FDA talks on anal cancer drug
Brief: Oncolytics Biotech® Announces Type C FDA Meeting To Discuss Single-Arm Registrational Pathway For Pelareorep In Anal Cancer
Advisory: Alert from Equity-Insider.com was published in error and has been withdrawn
U.S. STOCKS ON THE MOVE-Viking, Valvoline, Alphabet
U.S. STOCKS ON THE MOVE-Constellation Energy, Williams-Sonoma
Brief: Oncolytics Biotech® Provides Updated Clinical Safety Data For Pelareorep, Including Across Multiple Gastrointestinal Tumors
Brief: Oncolytics Biotech® Provides Updated Clinical Safety Data For Pelareorep, Including Across Multiple Gastrointestinal Tumors
Oncolytics Biotech jumps after pancreatic cancer therapy gets regulatory nod
U.S. STOCKS ON THE MOVE-Gold miners, Kroger, Dollar General, Nutanix
Brief: Oncolytics Biotech Receives Final Advice Letter From European Medicines Agency For Reolysin In Metastatic Breast Cancer